Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-10-17
DOI
10.3389/fimmu.2022.1023023
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
- (2021) Jacob Handlos Grauslund et al. Frontiers in Oncology
- Arginase 1-based immune modulatory vaccines induce anti-cancer immunity and synergize with anti-PD-1 checkpoint blockade
- (2021) Mia Aaboe Jørgensen et al. Cancer Immunology Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- (2021) Julie Westerlin Kjeldsen et al. NATURE MEDICINE
- Peripheral memory T cells specific for Arginase-1
- (2019) Evelina Martinenaite et al. Cellular & Molecular Immunology
- 440OPhase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours
- (2019) A Naing et al. ANNALS OF ONCOLOGY
- Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope
- (2019) Evelina Martinenaite et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Balance Players of the Adaptive Immune System
- (2018) Mads Hald Andersen CANCER RESEARCH
- Clinical relevance and suppressive capacity of human MDSC subsets
- (2018) Stephan Lang et al. CLINICAL CANCER RESEARCH
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Current landscape of immune therapy in treatment of solid tumours, with future opportunities and challenges.
- (2018) N. A. Nixon et al. Current Oncology
- Frequent adaptive immune responses against arginase-1
- (2017) Evelina Martinenaite et al. OncoImmunology
- Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
- (2017) Susanne M. Steggerda et al. Journal for ImmunoTherapy of Cancer
- L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
- (2016) Roger Geiger et al. CELL
- Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
- (2015) Stefano Ugel et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course
- (2015) An Coosemans et al. OncoImmunology
- Myeloid-derived suppressor cell heterogeneity in human cancers
- (2014) Samantha Solito et al. Annals of the New York Academy of Sciences
- The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
- (2012) Dennis Lindau et al. IMMUNOLOGY
- Myeloid-derived Suppressor Cells in Cancer Patients
- (2012) Alberto J. Montero et al. JOURNAL OF IMMUNOTHERAPY
- Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients
- (2012) Jana de Boniface et al. OncoImmunology
- Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes
- (2009) Paulo C. Rodriguez et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now